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radiotherapy patients. Simple radiation protection models 
should be used only with extreme care for risk estimates in 
radiotherapy, since they are developed exclusively for low 
dose. When applied to scatter radiation, such models can 
predict only a fraction of observed second malignancies. 
Better semi-empirical models include the effect of dose 
fractionation and represent the dose-response relationships 
more accurately. The involved uncertainties are still huge for 
most organs and tissues. A major reason for this is that the 
underlying processes of the induction of carcinoma and 
sarcoma are not well known. Most uncertainties are related 
to the time patterns of cancer induction, the population 
specific dependencies and to the organ specific cancer 
induction rates. For radiotherapy treatment plan 
optimization these factors are irrelevant, as a treatment plan 
comparison is performed for a patient of specific age, sex, 
etc. If a treatment plan is compared relative to another one 
only the shape of the dose-response curve (the so called risk-
equivalent dose) is of importance and errors can be 
minimized. One of the largest remaining uncertainties is the 
precision of the dose distribution which is the basic input into 
all risk-estimate-models. Dose calculation and/or 
measurement are as precise as approximately 5% in the 
treated volume of the patient. However, in the periphery 
dose errors can reach 100% and more. The use of erroneous 
dose data (see Figure 1) can lead to wrong risk estimates. 
Therefore a lot of effort is undertaken to produce precise 
dose computations in the whole patient volume about which 
is reported. Strategies are discussed how to include relevant 
dose information into cancer registries. 
Figure 1. Two dose comparisons of the same radiation 
treatment techniques which were used for risk estimates. 
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The association between radiation exposure and cancer risk 
has been studied for several decades, although in the clinical 
oncology setting, significant gaps in the understanding and 
management of radiation therapy (RT) related second cancer 
risks still exist. 
This talk will address the clinical implications of current 
knowledge relating to treatment- related second cancers, 
including:  
1. Treatment selection: Some clinicians or patients may opt 
to avoid RT in order to reduce the risk of second cancers. 
These decisions often reveal important misunderstandings 
about the impact of age, competing risks of death or other 
morbidity, and differences between absolute and relative 
risks. Through a case-based approach, participants will learn 
to identify scenarios in which over- or under-estimation of 
second cancer risk may lead to suboptimal treatment 
choices.  
2. Modification of Radiation Treatment: Oncologists are able 
to deliver dose much more precisely than ever before, but it 
remains difficult to decide where to deposit excess dose, or 
if low doses to large volumes are more carcinogenic than high 
doses to small volumes. The emergence of proton therapy 
now adds further complexity to these issues. In this session, 
participants will learn about dose-risk relationships and the 
clinical implications for radiotherapy planning. 
2. Clinical management in follow-up: Survivorship care is of 
growing clinical concern, and management of second cancer 
risk is an important feature of this care. Oncologists will be 
required to have familiarity with guidelines recommending 
specific screening interventions following RT. Participants 
will learn about resources and guidelines for management of 
second cancer risk, and the evidence supporting these 
guidelines will be reviewed. 
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Purpose or Objective: The influence of HPV positivity on 
therapy response in head and neck squamous cell cancers 
(HNSCC) highlights the importance of uniform and robust 
biomarkers for stratification of HNSCC patients. Our previous 
report indicates that p16 is not only a surrogate marker for 
HPV infections but has an active role in modulation of 
radiotherapy response by impairing DNA damage response 
and repair, which is a process known to be dominant in the 
nucleus of the cells. Based on this, we hypothesized that p16 
compartmentalization according to nuclear and cytoplasmic 
expression may have a role in risk stratification. 
 
Material and Methods: p16 expression (immunostaining) and 
HPV status (GP5+/6+ PCR) was assessed in 241 pretreatment 
biopsies of oropharyngeal cancer patients treated with 
chemoradiotherapy. Tumors were classified in nuclear p16 
expressing (>10% of tumor cells), cytoplasmic (>10% tumor 
cells) and p16 negative groups. Statistical analysis was 
performed to assess the correlation between clinical and 
tumor characteristics and p16 immunostaining. Influence of 
p16 localization on radiotherapy response was further 
assessed by clonogenic and cell survival assays in HPV/p16 
negative HNSCC cells transfected with viral construct 
containing p16-NLS (nuclear localization signal); p16-NES 
(nuclear exit signal) and p16-WT. The expression and 
localization of p16 was confirmed by western blotting and 
immunofluorescence. The response of p16 localization on 
DNA damage response and homologous recombination repair 
(HRR) was assessed by gH2AX, RAD51 foci formation and 
immunoprecipitation. 
 
Results: Nuclear p16 expressing HNSCC showed significant 
(p<0.05) better locoregional control rates (5-year 82%) 
compared to cytoplasmic p16 positive (5-year 55%) and p16 
negative patients (5-year 48%). Only nuclear p16 expression 
was a significant prognostic factor for locoregional control 
with a hazard ratio of 0.48 (p<0.05; 95% CI: 0.22-1.01). 
Interestingly, HPV positive patients were significantly 
enriched in the nuclear p16 expressing group (60%) compared 
to cytoplasmic p16 expressing group (9%). In concordance 
with our patient data, cells containing nuclear p16 expression 
(p16-NLS) showed a higher radiosensitization compared to 
cells with predominant cytoplasmic p16 expression (p16-NES) 
